Artificial intelligence–based detection of treatment-emergent metastatic neuroendocrine carcinoma of prostate.

C Chien-Kuang Cornelia Ding C Carolina Gomes-Alexandre (Johns Hopkins University, Baltimore, MD) L Lia De Paula Oliveira (Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD) S Sanaz Nourmohammadi Abadchi B Brendan Raizenne (University of California, San Francisco, San Francisco, CA) E Eric Erak (Brigham and Women's Hospital, Boston, MA) N Nilanjan Chattopadhyay (AIRA Matrix, Thane, India) U Uttara Joshi (AIRA Matrix, Thane, India) C Chaith Kondragunta (AIRA Matrix, Thane, India) N Nitin Singhal (AIRA Matrix, Thane, India) D David Quigley (Department of Physics, University of Warwick 2 , Gibbet Hill Road, Coventry CV4 7AL,) J Jiaoti Huang (From the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda (A.B.A., N.S., S.N., L.L., L.C.), the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.), and the Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Rockville (H.S., E.S.) — all in Maryland; the Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN (K.V.B., M.O., C.M., G.P.B.); AdventHealth Cancer Institute and the University of Central Florida, Orlando (G.S.); Dana–Farber/Harvard Cancer Center, Boston (S.B., B.M.); UNC Lineberger Comprehensive Cancer Center, Chapel Hill (W.Y.K.), and Duke University Medical Center and Duke Cancer Institute, Durham (J.H., S.H.) — both in North Carolina; the University of Kansas Cancer Center, Westwood (R.P.); Memorial Sloan Kettering Cancer Center, New York (M.Y.T., M.J.M., J.E.R.), and Roswell Park Comprehensive Cancer Center, Buffalo (G.C.) — both in...) E Eric J. Small A Angelo M. De Marzo (Johns Hopkins University Department of Biophysics, Baltimore, MD) T Tamara L. Lotan

Abstract

36 Background: Metastatic prostate carcinoma is a highly heterogeneous disease with a wide morphological spectrum and disease outcomes. While some retain adenocarcinoma morphology, some undergo lineage plasticity and transform into treatment emergent neuroendocrine carcinoma (t-NEPC) with morphology similarity to small cell carcinoma and highly aggressive disease behavior. We developed a morphology-based artificial intelligence (AI) tool applicable in real-world metastatic biopsies to assist the diagnosis of t-NEPC on digital whole-slide images (WSIs). Methods: Using a previously presented deep-learning based supervised learning algorithm, which was trained with localized prostate specimens with NEPC morphology in whole slide images (WSIs) using a custom-designed UNet model, here we fine tuned this algorithm using 62 metastatic biopsies from our institution with WSIs of H&E sections (enriched for t-NEPC, n=15, 24%), bench marking with GU pathologist’s diagnosis (adenocarcinoma vs. poorly differentiated carcinoma vs. t-NEPC) to generate a continuous t-NEPC score (range 0-1, with 1 most likely represent t-NEPC) for each slide. The algorithm was further tested in a non-overlapping external cohort (West Coast Dream Team and PROMOTE cohorts) of 167 metastatic biopsies with H&E WSIs (including 7 t-NEPC, 4%). Results: In our institutional cohort for fine tuning (n=62), t-NEPC score was significantly higher in 15 cases with a pathology diagnosis of t-NEPC compared to those with adenocarcinoma or poorly differentiated carcinoma. Using t-NEPC score >0.05 as a cutoff, the concordance rate between the AI t-NEPC score and pathologists was 94% t-NEPC and 56% for adenocarcinoma. In the validation cohort (West Coast Dream Team and PROMOTE, n=167), the algorithm still separated t-NEPC from adenocarcinoma, but not significantly in poorly differentiated carcinoma, with a concordance rate 71% for t-NEPC 77% for adenocarcinoma. Conclusions: As a proof-of-principle study, a morphology-based AI t-NEPC score established from a localized NEPC classifier was applicable towards the diagnosis of t-NEPC with a high concordance rate with GU pathologists. Adenocarcinoma Poorly differentiated Carcinoma t-NEPC Institutional cohort (n=62)  N, % 34, 55% 12, 19% 15, 24%  t-NEPC score (mean, +/- STD) 0.14, 0.20 0.09, 0.15 0.38, 0.21  Concordance (n, %) 19/34, 56% N/A 14/15, 94% West Coast Dream Team and PROMOTE cohorts (n=162)  N, % 100, 62% 60, 37% 7, 4%  t-NEPC score (mean, +/- STD) 0.05, 0.12 0.08, 0.17 0.24, 0.33  Concordance (n, %) 77/100, 77% N/A 5/7, 71%

Article Details

Volume / Issue Vol. 44, Issue 7_suppl
Published March 01, 2026
Pages 36-36
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (15)

C

Chien-Kuang Cornelia Ding

C

Carolina Gomes-Alexandre

Johns Hopkins University, Baltimore, MD

L

Lia De Paula Oliveira

Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD

S

Sanaz Nourmohammadi Abadchi

B

Brendan Raizenne

University of California, San Francisco, San Francisco, CA

E

Eric Erak

Brigham and Women's Hospital, Boston, MA

N

Nilanjan Chattopadhyay

AIRA Matrix, Thane, India

U

Uttara Joshi

AIRA Matrix, Thane, India

C

Chaith Kondragunta

AIRA Matrix, Thane, India

N

Nitin Singhal

AIRA Matrix, Thane, India

D

David Quigley

Department of Physics, University of Warwick 2 , Gibbet Hill Road, Coventry CV4 7AL,

J

Jiaoti Huang

From the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda (A.B.A., N.S., S.N., L.L., L.C.), the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.), and the Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Rockville (H.S., E.S.) — all in Maryland; the Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN (K.V.B., M.O., C.M., G.P.B.); AdventHealth Cancer Institute and the University of Central Florida, Orlando (G.S.); Dana–Farber/Harvard Cancer Center, Boston (S.B., B.M.); UNC Lineberger Comprehensive Cancer Center, Chapel Hill (W.Y.K.), and Duke University Medical Center and Duke Cancer Institute, Durham (J.H., S.H.) — both in North Carolina; the University of Kansas Cancer Center, Westwood (R.P.); Memorial Sloan Kettering Cancer Center, New York (M.Y.T., M.J.M., J.E.R.), and Roswell Park Comprehensive Cancer Center, Buffalo (G.C.) — both in...

E

Eric J. Small

A

Angelo M. De Marzo

Johns Hopkins University Department of Biophysics, Baltimore, MD

T

Tamara L. Lotan